English Description: Olmevas HZ (Olmesartan Medoxomil + Hydrochlorothiazide)

Olmevas HZ is a combination antihypertensive medication used for the treatment of high blood pressure (hypertension). It combines the blood pressure-lowering effects of Olmesartan, an angiotensin II receptor blocker (ARB), and Hydrochlorothiazide, a thiazide diuretic, to provide effective blood pressure control.

Key Features:

Helps lower elevated blood pressure
Reduces the risk of cardiovascular complications associated with hypertension
Combines dual mechanisms for enhanced blood pressure control
Once-daily dosing for convenient administration

Pharmacology

Olmesartan Medoxomil

Blocks the action of angiotensin II at AT1 receptors
Relaxes blood vessels and lowers blood pressure
Reduces aldosterone secretion

Hydrochlorothiazide

Increases excretion of sodium and water through the kidneys
Reduces blood volume, helping lower blood pressure
Works synergistically with Olmesartan

Dosage & Administration

Usual starting dose: 20 mg/12.5 mg once daily
Dose may be adjusted according to blood pressure response
Maximum recommended dose: 40 mg/25 mg once daily
Dose titration is generally done at intervals of 2-4 weeks

Side Effects

Common side effects may include:

Headache
Dizziness
Nausea
Hyperuricemia
Upper respiratory tract infection
Urinary tract infection
Abdominal pain
Diarrhea
Dyspepsia
Peripheral edema

Contraindications

Hypersensitivity to Olmesartan, Hydrochlorothiazide, or any component of the formulation
Anuria
Hypersensitivity to sulfonamide-derived drugs

Precautions

Regular monitoring of serum electrolytes is recommended
Use cautiously in patients with impaired kidney function
Hyperuricemia may occur during therapy
Elderly patients may require careful dose selection